146 related articles for article (PubMed ID: 35932122)
1. Systemic Immune Inflammation Index as a Key Marker of Survival and Immune-related Adverse Events in Immune Checkpoint Inhibitor Therapy.
Ekinci F; Balcik OY; Demir B; Gursoy P; Ozveren A; Erdogan AP
J Coll Physicians Surg Pak; 2022 Aug; 32(8):996-1003. PubMed ID: 35932122
[TBL] [Abstract][Full Text] [Related]
2. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
3. HALP Score as a New Prognostic Index in Metastatic Renal Cell Cancer.
Ekinci F; Balcik OY; Oktay E; Erdogan AP
J Coll Physicians Surg Pak; 2022 Mar; 32(3):313-318. PubMed ID: 35148582
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors.
Mesti T; Grašič Kuhar C; Ocvirk J
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979727
[TBL] [Abstract][Full Text] [Related]
5. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory Prognostic Index in Metastatic Renal Carcinoma Treated with Nivolumab.
Ekinci F; Erdogan AP; Yildirim S; Bulut G; Yilmaz C; Barutca S
J Coll Physicians Surg Pak; 2022 Oct; 32(10):1288-1294. PubMed ID: 36205273
[TBL] [Abstract][Full Text] [Related]
7. Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study.
Zheng F; Meng Q; Zhang L; Chen J; Zhao L; Zhou Z; Liu Y
World J Surg Oncol; 2023 Jul; 21(1):198. PubMed ID: 37420219
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients.
Shi X; Li H; Xu Y; Nyalali AMK; Li F
Neurol Sci; 2022 Sep; 43(9):5523-5531. PubMed ID: 35606674
[TBL] [Abstract][Full Text] [Related]
9. Systemic Immune-inflammation Index is the Best Prognostic Factor in Patients with Advanced Stage Adenocarcinoma of the Lung Treated with Pemetrexed.
Bilgetekin I; Basal FB
J Coll Physicians Surg Pak; 2020 Sep; 30(9):933-939. PubMed ID: 33036677
[TBL] [Abstract][Full Text] [Related]
10. HALP Score as a New Prognostic Factor for Patients with Metastatic Bladder Cancer.
Acar O; Ayhan M; Demir B; Ekinci F; Aytac A; Erdogan AP
J Coll Physicians Surg Pak; 2023 Dec; 33(12):1405-1409. PubMed ID: 38062597
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
[No Abstract] [Full Text] [Related]
12. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
13. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of pre-treatment systemic immune-inflammation index in patients with endometrial cancer.
Matsubara S; Mabuchi S; Takeda Y; Kawahara N; Kobayashi H
PLoS One; 2021; 16(5):e0248871. PubMed ID: 33989285
[TBL] [Abstract][Full Text] [Related]
15. Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis.
Tian BW; Yang YF; Yang CC; Yan LJ; Ding ZN; Liu H; Xue JS; Dong ZR; Chen ZQ; Hong JG; Wang DX; Han CL; Mao XC; Li T
Immunotherapy; 2022 Dec; 14(18):1481-1496. PubMed ID: 36537255
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
[TBL] [Abstract][Full Text] [Related]
17. Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria.
Fu H; Zheng J; Cai J; Zeng K; Yao J; Chen L; Li H; Zhang J; Zhang Y; Zhao H; Yang Y
Cell Physiol Biochem; 2018; 47(1):293-301. PubMed ID: 29768257
[TBL] [Abstract][Full Text] [Related]
18. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
[No Abstract] [Full Text] [Related]
19. Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide.
Topkan E; Besen AA; Ozdemir Y; Kucuk A; Mertsoylu H; Pehlivan B; Selek U
Mediators Inflamm; 2020; 2020():4392189. PubMed ID: 32565725
[TBL] [Abstract][Full Text] [Related]
20. Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patients.
Ma C; Yu R; Li J; Guo J; Xu J; Wang X; Liu P
J Surg Oncol; 2022 Mar; 125(4):754-765. PubMed ID: 34811745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
